TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02599090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Groups 1 \& 2: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m\^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m\^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 \& 4: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m\^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle.
Study: NCT01130519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Commercially available. Administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Commercially available. Administered orally.
Study: NCT03566875

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty with the Stryker's MAKO™ system
Description: The robot assisted surgery is performed using the Stryker's MAKO™ system. The precision with this system is very accurate. It should help the surgeon to improve the positioning accuracy of prosthetic implants compared to the conventional method.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty with mechanical ancillary
Description: The arthroplasty is performed with the mechanical ancillary refering to the the conventional method.
Study: NCT03912532

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282
Description: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282
Description: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282
Description: NGM282

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for NGM282
Study: NCT00307632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norelgestromine (NLGM)/ethinyl estradiol (EE)
Description: Participants will apply a 20 centimeter square (cm\^2) contraceptive transdermal patch on the skin for 1 full week, and then apply a fresh patch for Week 2, and a third patch for Week 3. The fourth week will be patch-free. Each patch delivers 150 microgram (mcg) of NLGM and 20 mcg of EE per day. The treatment duration is of 6 cycles (4 weeks each).
Study: NCT01972451

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy with enhanced dye

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colonoscopy with enhanced dye
Study: NCT00707902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine/lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: echinacea/sage
Study: NCT01250132

Intervention type: OTHER
Group type: OTHER
Intervention: Biological and behavioral explorations
Description: Blood dosages:~* biochemistry~* pituitary gland~* somatotropic axis~* corticotropic axis~* gonadotropic axis~* thyrotropic axis~* antidiuretic axis~Questionnaires and scales (quality of life, Vineland Adaptive Behavior Scales (VABS)-II)
Study: NCT01328548

Intervention type: DRUG
Intervention: Zostavax

Intervention type: DRUG
Intervention: Zostavax

Intervention type: DRUG
Intervention: Zostavax
Study: NCT01440140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed-loop
Description: Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional insulin pump delivery
Description: Subcutaneous delivery of Novorapid insulin according to usual pump regime
Study: NCT04682262

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical dilatation
Description: Patients undergo to cervical dilatation prior to the hysteroscopy under general anaesthesia with using Hegar dilator (no.10)
Study: NCT02987972

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 Lot 1
Description: Lot 1: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 Lot 2
Description: Lot 2: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
Study: NCT01149421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered as a subcutaneous injection once weekly for 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered as a subcutaneous injection once weekly for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a subcutaneous injection once weekly for 26 weeks
Study: NCT05909813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Piano Keyboard Instruction
Description: During weeks two through seven, participants will receive a once a week, hour long, in-person individualized piano keyboard instruction as follows:~1. Warm-up~   1. Scales and Chords: Consisting of scales on seven major keys (C, D, E, F, G, A and B), chord progressions on I, IV, V, I. Two different keys will be learned every week.~  2. 5-finger exercises will be completed four times per week.~2. Piano Theory and Music~   1. Piano Theory: Playing through Alfred's Basic Adult All-in-One Course, Book 1, to be completed at the ability level of participant, with a least two new pages per lesson.~  2. Chosen Piece: Playing through an instrumental piece chosen by the participant.~Participants will be asked to practice homework from this lesson daily for 20 minutes per day, until their next weekly lesson.
Study: NCT01725932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally adapted CBT based Self Help
Description: Intervention was based on our initial work using mixed methods, using mixed methods,in Pakistan. It focused on psycho-education, symptoms management, changing negative thinking, behavioral activation, problem solving, improving relationships and communication skills. One person from the family was involved in all cases. The intervention consists of 7 chapters. Manual can be used by the patient's or carers with at least 5 years of education. A member of the research team called them once every week to remind them of the next chapter and also to discuss any issues o problems that emerged during the previous week. This manual can be downloaded from PACT website (http://www.pactorganization.com/)
Study: NCT04615806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green solution
Description: ICG solution was endoscopically injected into the esophageal submucosa at the four quadrants around the tumor.
Study: NCT03043157

Intervention type: DRUG
Group type: OTHER
Intervention: rocuronium
Description: intravenous rocuronium infusion
Study: NCT02718183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide 35% (Opalescence Endo - Ultradent, USA)
Description: bleaching teeth gel to intracameral use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: carbamide peroxide 37% (Whiteness Superendo, FGM, Brazil).
Description: bleaching teeth gel to intracameral use.
Study: NCT06060106

Intervention type: PROCEDURE
Intervention: Endoscopic submucosal dissection
Description: The patient was positioned in the left lateral decubitus position.Marking dots were made with a dual knife/hybrid knife around the lesion, and a solution of glycerin fructose with indigo carmine was injected into the submucosal layer to lift the lesion. Finally, after pre-cutting of the mucosal and submucosal layers around the lesion and dissection of the submucosa, the lesion was removed en bloc.

Intervention type: PROCEDURE
Intervention: Esophagectomy
Description: The main surgical methods of esophagectomy include the McKeown operation, Lvor-lewis, Sweet and minimally invasive radical resection of esophageal cancer (MIE)
Study: NCT02286648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: pulpotomy with formocresol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Description: pulpotomy with MTA
Study: NCT01560533

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interviews
Description: Interviews will be done with patients

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interviews
Description: Interviews will be done with patients
Study: NCT00846703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-mercaptopurine, Methotrexate
Description: 6-mercaptopurine p.o. qd~Methotrexate p.o. qw

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
Description: (1)6-mercaptopurine p.o. qd x 7w Methotrexate p.o. qd x 7w~(2)Vincristine qw x 1w Dexamethasone p.o. qd x 7d~Go to (1) and (2)
Study: NCT02549976

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal MRI
Description: Abdominal MRI to realize within 4 months following inclusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper endoscopy
Description: Upper endoscopy to realize within 4 months following inclusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Colonoscopy to realize within 4 months following inclusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic MRI
Description: Pelvic MRI to realize within 4 months following inclusion
Study: NCT03471728

Intervention type: DRUG
Intervention: linaclotide
Description: Oral

Intervention type: DRUG
Intervention: linaclotide
Description: Oral
Study: NCT03616444

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Shenbai Granules
Description: In the first year, the trial granules will be started after enrollment for 3 months; In the second year, the trial granules will be started in the first 3 months; Each participant should have completed 6 months of trial granules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenbai Granules
Description: In the first year, the trial granules will be started after enrollment for 3 months; In the second year, the trial granules will be started in the first 3 months; Each participant should have completed 6 months of trial granules.
Study: NCT01373112

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Static Spacer
Description: After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Articulating Spacer
Description: After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
Study: NCT02273271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-FLT-PET/CT and DWI-MRI
Description: Patients with NSCLC will undergo 18F-FLT-PET/CT and DWI-MRI scans on three separate occasions. Dedicated in-house developed software will be used to quantify 18F-FLT SUV and ADC to assess tumor characteristics and response to therapy.
Study: NCT00170313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conducted AF-Response Algorithm (CAFR) On
Description: Algorithm will be enabled.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conducted AF-Response Algorithm (CAFR) Off
Description: Algorithm will be disabled.
Study: NCT01953432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: Doxazosin is initiated at 2 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 4 weeks. Participants will be maintained on 8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo daily dosing
Study: NCT02183805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane,Cyclophosphamide,Carboplatin
Description: High dose chemotherapy: Abraxane, Cyclophosphamide, Carboplatin
Study: NCT01632150

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Powder for solution, 400-mg vials, for infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 50-mg capsules administered orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 2- and 4-mg tablets (and various other strengths, as needed) administered orally and in 4- and 8-mg/mL (and various other strengths, as needed) solutions for intravenous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50-mg tablets administered orally
Study: NCT05248295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unison speech (vs. solo)
Description: Participants will repeat sentences in four conditions, in a 2x2 design with the factors unison vs. solo repetition, and metrical vs. conversational speech timing. Measures of speech accuracy and timing will be collected.
Study: NCT02852668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power Training
Description: This experimental groups underwent an intervention period of power training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: This experimental groups underwent an intervention period of strength training
Study: NCT03176667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided erector spinae plane block
Description: A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T5 spinous process. The trapezius, rhomboid major, and erector spinae muscles will then be identified superficial to the tip of the T5 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.5% ropivacaine with 5mcg/mL of epinephrine will be injected in 5-mL aliquots through the needle (maximum of 3mg/kg), followed by insertion of a 19-gauge catheter under direct vision 5 cm beyond the needle tip. The catheter will then be secured in place.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal block
Description: The surgeons will identify the desired rib, and advance the needle at an approximately 20-degree angle until contact with rib is made, the needle is then walked of the inferior border of the rib and advanced slightly to plaice the tip of the needle in the neurovascular bundle. The intercostal nerve blocks will be performed at T4-T11 using 0.25% Marcaine with epinephrine and a volume of 5 ml per block (maximum of 2.5mg/kg) after negative aspiration has been confirmed.
Study: NCT04057911

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NIBS
Description: The electrode placement will be same, but the electric current will be ramped down 5 seconds after the beginning of the stimulation
Study: NCT02013661

Intervention type: PROCEDURE
Intervention: Periodontal resective surgery
Description: surgical periodontal debridement is performed after periodontal phase I
Study: NCT01758107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Withdraw cyclosporine
Study: NCT02382237

Intervention type: DEVICE
Group type: OTHER
Intervention: PET/TDM
Description: Evaluation of nutrition absorption by TEP/TDM
Study: NCT04867876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Management of urinary incontinence by a physical therapist will include but is not limited to biofeedback, dietary management, alleviation of constipation, and neuromuscular re-education.
Study: NCT06623500

Intervention type: DIETARY_SUPPLEMENT
Intervention: Iodine excess
Description: Iodine excess areas: water iodine ≥100μg/L; or urinary iodine concentration (median urinary iodine levels in children aged 8-10 years old)≥300μg/L

Intervention type: DIETARY_SUPPLEMENT
Intervention: Iodine suitable
Description: Iodine suitable areas：water iodine ≥40μg/L and ≤100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) 100-199μg/L.
Study: NCT02235051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Undergo Curves exercise program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT02279745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ralinepag
Description: Active
Study: NCT04561102

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test for detection of SARS-CoV-2
Description: The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19
Study: NCT01575275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study: NCT02413242

Intervention type: OTHER
Intervention: Various observed exposure(s) of interest
Description: A risk prediction model will be developed to assess which risk factors are associated with the development of ICU pneumonia during ICU stay

Intervention type: OTHER
Intervention: Various observed exposure(s) of interest
Description: A risk prediction model will be developed to assess which risk factors are associated with the development of ICU pneumonia during ICU stay
Study: NCT03588078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246
Description: Azacitidine at maximum tolerated dose. APR246 at the Dose limited Toxicity (DLT) dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m2
Study: NCT04112160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: IM injection of either normal saline or Ketorolac

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline
Study: NCT01503398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine Tablets, 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine Tablets, 5 mg
Study: NCT00570544

Intervention type: DRUG
Intervention: tiotropium
Description: 18ug capsule daily for 30 days
Study: NCT00108342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine gum - 2 mg and 4 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine lozenges - 2 mg and 4 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine inhaler (4 mg yield) - low and high dosage by frequency of puffing
Description: can yield 4 mg from 10 mg device - infrequent and frequent puffing

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Computer learning
Study: NCT01451944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education
Description: home asthma case management and education
Study: NCT02052596

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herpes Zoster vaccine GSK 1437173A
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster vaccine GSK 1437173A
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: 1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix
Description: 1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.
Study: NCT02362776

Intervention type: OTHER
Intervention: Venous blood sample
Description: Collection of a venous blood sample to investigate metabolic changes in blood
Study: NCT00453310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Study: NCT00783471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib, Docetaxel
Description: Drug: Erlotinib 150 mg po daily, days 1-12 Drug: Docetaxel 75 mg/m2 IV over 30 min on day 15 Treatment will be repeated every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Erlotinib
Description: Drug: Docetaxel 75 mg/m2 IV over 30 min on day 1 Drug: Erlotinib 150 mg po daily, days 4-15 Treatment will be repeated every 21 days
Study: NCT02183350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS - single rising dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04059393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Complete web-based legacy intervention
Study: NCT01448382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam® capsule with Given PillCam® Platform
Description: capsule endoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam® capsule with Given PillCam® Platform
Description: capsule endoscopy